Cargando…
Microbiomes, Epigenomics, Immune Response, and Splicing Signatures Interplay: Potential Use of Combination of Regulatory Pathways as Targets for Malignant Mesothelioma
Malignant mesotheliomas (MM) are hard to treat malignancies with poor prognosis and high mortality rates. This cancer is highly misdiagnosed in Sub-Saharan African countries. According to literature, the incidence of MM is likely to increase particularly in low-middle-income countries (LMICs). The b...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409175/ https://www.ncbi.nlm.nih.gov/pubmed/36012262 http://dx.doi.org/10.3390/ijms23168991 |
_version_ | 1784774786297102336 |
---|---|
author | Setlai, Botle Precious Mkhize-Kwitshana, Zilungile Lynette Mehrotra, Ravi Mulaudzi, Thanyani Victor Dlamini, Zodwa |
author_facet | Setlai, Botle Precious Mkhize-Kwitshana, Zilungile Lynette Mehrotra, Ravi Mulaudzi, Thanyani Victor Dlamini, Zodwa |
author_sort | Setlai, Botle Precious |
collection | PubMed |
description | Malignant mesotheliomas (MM) are hard to treat malignancies with poor prognosis and high mortality rates. This cancer is highly misdiagnosed in Sub-Saharan African countries. According to literature, the incidence of MM is likely to increase particularly in low-middle-income countries (LMICs). The burden of asbestos-induced diseases was estimated to be about 231,000 per annum. Lack of awareness and implementation of regulatory frameworks to control exposure to asbestos fibers contributes to the expected increase. Exposure to asbestos fibers can lead to cancer initiation by several mechanisms. Asbestos-induced epigenetic modifications of gene expression machinery and non-coding RNAs promote cancer initiation and progression. Furthermore, microbiome–epigenetic interactions control the innate and adaptive immunity causing exacerbation of cancer progression and therapeutic resistance. This review discusses epigenetic mechanisms with more focus on miRNAs and their interaction with the microbiome. The potential use of epigenetic alterations and microbiota as specific biomarkers to aid in the early detection and/or development of therapeutic targets is explored. The advancement of combinatorial therapies to prolong overall patient survival or possible eradication of MM especially if it is detected early is discussed. |
format | Online Article Text |
id | pubmed-9409175 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94091752022-08-26 Microbiomes, Epigenomics, Immune Response, and Splicing Signatures Interplay: Potential Use of Combination of Regulatory Pathways as Targets for Malignant Mesothelioma Setlai, Botle Precious Mkhize-Kwitshana, Zilungile Lynette Mehrotra, Ravi Mulaudzi, Thanyani Victor Dlamini, Zodwa Int J Mol Sci Review Malignant mesotheliomas (MM) are hard to treat malignancies with poor prognosis and high mortality rates. This cancer is highly misdiagnosed in Sub-Saharan African countries. According to literature, the incidence of MM is likely to increase particularly in low-middle-income countries (LMICs). The burden of asbestos-induced diseases was estimated to be about 231,000 per annum. Lack of awareness and implementation of regulatory frameworks to control exposure to asbestos fibers contributes to the expected increase. Exposure to asbestos fibers can lead to cancer initiation by several mechanisms. Asbestos-induced epigenetic modifications of gene expression machinery and non-coding RNAs promote cancer initiation and progression. Furthermore, microbiome–epigenetic interactions control the innate and adaptive immunity causing exacerbation of cancer progression and therapeutic resistance. This review discusses epigenetic mechanisms with more focus on miRNAs and their interaction with the microbiome. The potential use of epigenetic alterations and microbiota as specific biomarkers to aid in the early detection and/or development of therapeutic targets is explored. The advancement of combinatorial therapies to prolong overall patient survival or possible eradication of MM especially if it is detected early is discussed. MDPI 2022-08-12 /pmc/articles/PMC9409175/ /pubmed/36012262 http://dx.doi.org/10.3390/ijms23168991 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Setlai, Botle Precious Mkhize-Kwitshana, Zilungile Lynette Mehrotra, Ravi Mulaudzi, Thanyani Victor Dlamini, Zodwa Microbiomes, Epigenomics, Immune Response, and Splicing Signatures Interplay: Potential Use of Combination of Regulatory Pathways as Targets for Malignant Mesothelioma |
title | Microbiomes, Epigenomics, Immune Response, and Splicing Signatures Interplay: Potential Use of Combination of Regulatory Pathways as Targets for Malignant Mesothelioma |
title_full | Microbiomes, Epigenomics, Immune Response, and Splicing Signatures Interplay: Potential Use of Combination of Regulatory Pathways as Targets for Malignant Mesothelioma |
title_fullStr | Microbiomes, Epigenomics, Immune Response, and Splicing Signatures Interplay: Potential Use of Combination of Regulatory Pathways as Targets for Malignant Mesothelioma |
title_full_unstemmed | Microbiomes, Epigenomics, Immune Response, and Splicing Signatures Interplay: Potential Use of Combination of Regulatory Pathways as Targets for Malignant Mesothelioma |
title_short | Microbiomes, Epigenomics, Immune Response, and Splicing Signatures Interplay: Potential Use of Combination of Regulatory Pathways as Targets for Malignant Mesothelioma |
title_sort | microbiomes, epigenomics, immune response, and splicing signatures interplay: potential use of combination of regulatory pathways as targets for malignant mesothelioma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409175/ https://www.ncbi.nlm.nih.gov/pubmed/36012262 http://dx.doi.org/10.3390/ijms23168991 |
work_keys_str_mv | AT setlaibotleprecious microbiomesepigenomicsimmuneresponseandsplicingsignaturesinterplaypotentialuseofcombinationofregulatorypathwaysastargetsformalignantmesothelioma AT mkhizekwitshanazilungilelynette microbiomesepigenomicsimmuneresponseandsplicingsignaturesinterplaypotentialuseofcombinationofregulatorypathwaysastargetsformalignantmesothelioma AT mehrotraravi microbiomesepigenomicsimmuneresponseandsplicingsignaturesinterplaypotentialuseofcombinationofregulatorypathwaysastargetsformalignantmesothelioma AT mulaudzithanyanivictor microbiomesepigenomicsimmuneresponseandsplicingsignaturesinterplaypotentialuseofcombinationofregulatorypathwaysastargetsformalignantmesothelioma AT dlaminizodwa microbiomesepigenomicsimmuneresponseandsplicingsignaturesinterplaypotentialuseofcombinationofregulatorypathwaysastargetsformalignantmesothelioma |